Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | AKT1 | P31749 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL995684 | 1.00 | KMT2A (0.42) | KMT2AMEN1AKT1LMNASMN1; SMN2 | |
| SCHEMBL998337 | 0.83 | — | — | |
| SCHEMBL998336 | 0.83 | — | — | |
| SCHEMBL997223 | 0.79 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL997225 | 0.79 | KMT2A (0.43) | KMT2AMEN1SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL7088747 | 0.78 | ALDH1A1 (0.50) | KMT2AMEN1LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL997290 | 0.74 | ACE (0.49) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL17848995 | 0.73 | MEP1B (0.47) | ALDH1A1 | |
| Acetic Acid SCHEMBL3369311 | 0.73 | ACE (0.48) | KMT2AMEN1LMNAALDH1A1POLB | |
| SCHEMBL7477929 | 0.73 | AKT1 (0.51) | KMT2AMEN1AKT1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998933-B2 | Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide | L'OREAL S.A. (FR) | 2011-08-16 | — | — | US | claimed |
| US-20110021438-A1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF | L'OREAL S.A. (FR) | 2011-01-27 | — | — | US | claimed |
| US-20080293962-A1 | Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof | L'OREAL S.A. (FR) | 2008-11-27 | — | — | US | claimed |
| US-7419970-B2 | Aging resistance; controlling skin elasticity; example: ethyl {2-[acetyl(3-trifluoromethyl-phenyl)amino]-3-methylbutyrylamino}acetate; of slowing down the degradation activity of the elastic fibres of the intercellular spaces, may make it possible to reduce this phenomenon of accelerated ageing of skin | L'OREAL (FR) | 2008-09-02 | — | — | US | claimed |
| US-20060211659-A9 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | DALKO MARIA | 2006-09-21 | — | — | US | claimed |
| US-6987128-B2 | Compounds of the N-acylamino amide family, compositions comprising same, and uses | L'OREAL S.A. (FR) | 2006-01-17 | — | — | US | claimed |
| US-20050187197-A1 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | DALKO MARIA (FR) | 2005-08-25 | — | — | US | claimed |
| EP-1292608-B1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | OREAL (FR) | 2004-07-21 | — | — | EP | claimed |
| US-20030152600-A1 | Novel compounds of the n-acylamino-amide-family, cpmpositions comprising same, and uses | L'OREAL S.A. (FR) | 2003-08-14 | — | — | US | claimed |
| US-7998933-B2 | Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide | L'OREAL S.A. (FR) | 2011-08-16 | — | — | US | disclosed |
| US-20110021438-A1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF | L'OREAL S.A. (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7786321-B2 | Compounds of the N-acylamino amide family compositions comprising them and uses thereof | L'OREAL S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080293962-A1 | Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof | L'OREAL S.A. (FR) | 2008-11-27 | — | — | US | disclosed |
| US-7419970-B2 | Aging resistance; controlling skin elasticity; example: ethyl {2-[acetyl(3-trifluoromethyl-phenyl)amino]-3-methylbutyrylamino}acetate; of slowing down the degradation activity of the elastic fibres of the intercellular spaces, may make it possible to reduce this phenomenon of accelerated ageing of skin | L'OREAL (FR) | 2008-09-02 | — | — | US | disclosed |
| US-20060211659-A9 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | DALKO MARIA | 2006-09-21 | — | — | US | disclosed |
| US-6987128-B2 | Compounds of the N-acylamino amide family, compositions comprising same, and uses | L'OREAL S.A. (FR) | 2006-01-17 | — | — | US | disclosed |
| US-20050187197-A1 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | DALKO MARIA (FR) | 2005-08-25 | — | — | US | disclosed |
| EP-1292608-B1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES | OREAL (FR) | 2004-07-21 | — | — | EP | disclosed |
| US-20030152600-A1 | Novel compounds of the n-acylamino-amide-family, cpmpositions comprising same, and uses | L'OREAL S.A. (FR) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293962-A1 | Novel compounds of the N-acylamino amide family compositions comprising them and uses thereof | AADAC, COL14A1, COL2A1 | KMT2A 861/4885MEN1 4348/4885AKT1 3586/4885 |
| US-20060211659-A9 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | AADAC, COL2A1, COL14A1 | KMT2A 651/4885MEN1 4273/4885AKT1 3611/4885 |
| US-20110021438-A1 | NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF | COL2A1, COL14A1, AADAC | KMT2A 1015/4885MEN1 4434/4885AKT1 3608/4885 |
| US-20050187197-A1 | Novel compounds of the N-acylamino amide family, compositions comprising them and uses thereof | AADAC, COL2A1, COL14A1 | KMT2A 651/4885MEN1 4273/4885AKT1 3611/4885 |
| US-20030152600-A1 | Novel compounds of the n-acylamino-amide-family, cpmpositions comprising same, and uses | COL1A1, COL14A1, COL2A1 | KMT2A 1121/4885MEN1 2412/4885AKT1 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.